ASCENDsecondary progressive multiple sclerosisnatalizumabinterferon β-1a
…ng for therapeutic lag.Methods We analysed pooled data from the ASCEND (natalizumab vs placebo) and SPECTRIMS (interferon β-1a vs plac…
Entity family
Universities, hospitals, research centres, networks, and public bodies. Examples include universities, NHS trusts, research networks.
This institution is selected. Its supporting articles are shown below.
…ng for therapeutic lag.Methods We analysed pooled data from the ASCEND (natalizumab vs placebo) and SPECTRIMS (interferon β-1a vs plac…